Pathogenic Forms of Tau Inhibit Kinesin-Dependent Axonal Transport through a Mechanism Involving Activation of Axonal Phosphotransferases
Open Access
- 6 July 2011
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 31 (27), 9858-9868
- https://doi.org/10.1523/jneurosci.0560-11.2011
Abstract
Aggregated filamentous forms of hyperphosphorylated tau (a microtubule-associated protein) represent pathological hallmarks of Alzheimer9s disease (AD) and other tauopathies. While axonal transport dysfunction is thought to represent a primary pathogenic factor in AD and other neurodegenerative diseases, the direct molecular link between pathogenic forms of tau and deficits in axonal transport remain unclear. Recently, we demonstrated that filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Here, we demonstrate that amino acids 2–18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway in axoplasms isolated from squid giant axons. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Importantly, immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity, an early marker of pathological tau. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT. Results from these studies reveal a novel role for tau in modulating axonal phosphotransferases and provide a molecular basis for a toxic gain-of-function associated with pathogenic forms of tau.Keywords
This publication has 52 references indexed in Scilit:
- Tau Reduction Prevents Aβ-Induced Defects in Axonal TransportScience, 2010
- Axonal Transport Defects in Neurodegenerative DiseasesJournal of Neuroscience, 2009
- The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicityJournal of Neuroscience Research, 2008
- A possible link between astrocyte activation and tau nitration in Alzheimer's diseaseNeurobiology of Disease, 2008
- Axonal Transport RatesIn VivoAre Unaffected by Tau Deletion or Overexpression in MiceJournal of Neuroscience, 2008
- Age‐related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerabilityJournal of Comparative Neurology, 2007
- Multiple-motor based transport and its regulation by TauProceedings of the National Academy of Sciences of the United States of America, 2007
- Global Hairpin Folding of Tau in SolutionBiochemistry, 2006
- Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205Neuroscience Letters, 1995
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991